TY - JOUR
T1 - HDL Cholesterol
T2 - Physiology, Pathophysiology, and Management
AU - Link, Jeffrey J.
AU - Rohatgi, Anand K
AU - de Lemos, James A
PY - 2007/5
Y1 - 2007/5
N2 - Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.
AB - Numerous epidemiological studies have identified high-density lipoprotein cholesterol (HDL) to be an independent risk factor for coronary heart disease (CHD). HDL is an emerging therapeutic target that could rival the impact of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on LDL and CHD risk reduction. HDL metabolism, HDL kinetics, the concentration of various HDL subclasses, and other genetic factors affecting HDL functionality may all contribute to the anti-atherogenic properties of HDL; thus, standard plasma measurement may not capture the full range of HDL effects. Algorithms have been suggested to treat low HDL levels in subgroups of patients; however, no formal HDL target goals or treatment guidelines have been implemented as there is a lack of strong clinical evidence to support effective pharmacologic therapy for primary risk reduction. Available therapies have a modest impact on serum HDL levels; however, emerging therapies could have a more significant influence.
UR - http://www.scopus.com/inward/record.url?scp=34247619743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247619743&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2007.01.004
DO - 10.1016/j.cpcardiol.2007.01.004
M3 - Article
C2 - 17481993
AN - SCOPUS:34247619743
SN - 0146-2806
VL - 32
SP - 268
EP - 314
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 5
ER -